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Patient samples were referred to our immunohematology 
reference laboratory to investigate the presence of a weak D 
antigen. In the last 3 years, 26 samples were received. Serology 
and molecular analyses were performed to identify the weak D 
variant. RHD mRNA from all patients was reverse transcribed, 
and cDNA was sequenced. The results were compared with a 
normal RHD sequence to identify the polymorphisms causing the 
weak D phenotype. Five different already known RHD variants 
were observed: weak D type 1 (5 individuals), weak D type 2 (1 
individual), weak D type 42 (17 individuals), weak D type 45 (1 
individual), and partial D DNB (2 individuals). Surprisingly, weak 
D type 42 was prevalent in our population, whereas weak D type 
1, 2, and 3 are the most prevalent variants elsewhere. Anti-D was 
found in six cases of weak D type 42. The higher prevalence of 
weak D type 42 could be the result of a founder effect. Additional 
studies are needed to estimate the frequency of this variant in the 
general population. Immunohematology 2011;27:20–24.
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The D antigen can induce Rh-incompatible blood 
transfusion reactions and hemolytic disease of the fetus 
and the newborn (HDFN). It is the next most clinically 
significant blood group antigen after ABO.1–5 The lack 
of RHD in 15 percent of Caucasians, 3 to 5 percent of 
Africans, and less than 1 percent of Asians and the extreme 
immunogenicity of its encoded D antigen explain the high 
incompatibility risk, which is of great concern for blood 
transfusion specialists.2,3,6
To prevent alloimmunization of D– recipients and 
to avoid the administration of D+ blood to patients who 
already have developed an alloanti-D, blood donor typing 
should identify all donors expressing the D antigen.3,4 
Unfortunately, the serologic distinction between D+ and 
D– RBCs is not always straightforward.7 This can be 
related to different reagents and to aberrant RHD alleles. 
Although hundreds of RHD variants have been described 
in the literature, they remain rare events with an estimated 
prevalence of 1 to 2 percent in Caucasians and slightly 
higher rates in African Americans and Hispanics.8 As of 
January 2011, 76 weak D alleles have been described (types 
1–76, plus 8 subtypes9).
These variants are classified according to the serology 
profile obtained with different anti-D reagents: weak 
D, partial D, and DEL, which is only demonstrated 
by adsorption-elution.5,10–14 Weak D phenotypes 
express a reduced amount of D antigen of otherwise 
unchanged quality as a result of point mutations in the 
membrane-spanning domains or cytoplasmic loops of 
the protein. Anti-D alloimmunization is unusual in these 
individuals.3,6,8,11,13,15–17
On the other hand, partial D phenotypes lack one 
or more epitopes of the D protein and present antigenic 
modifications caused by RHD/RHCE hybrid genes or 
RHD point mutations mostly affecting external loops 
of the protein.4–6 These individuals are prone to anti-D 
alloimmunization.
The weakest D phenotype, DEL, can only be detected 
by adsorption-elution techniques, from which it gets its 
name. Individuals with DEL phenotype are routinely 
typed as D– and are frequent in Asia.4 Molecular analyses 
have demonstrated that DEL samples retain an intact 
RHD or have a large RHD portion in their genome.5,13 
Transfusion specialists are still debating the potential 
alloimmunization risk as it relates to the classification 
of aberrant RHD alleles, especially of DEL donors and 
patients.5,18,19
Several studies have concluded that weak D type 1, type 
2, and type 3 are the most frequent, at least in Germany, 
Austria, the Netherlands, and France.20 In our cohort of 
patients, weak D type 42 seems to be the most prevalent, 
with 17 samples identified in the last 3 years. This weak 
D was first described in two Canadian blood donors by 
Denomme et al.7 In this study, we describe the serology and 
the molecular analyses done for these cases.
Materials and Methods
Serology
From October 2006 to January 2010, 26 Caucasian 
samples, all multi-generation French Canadians (4 men and 
22 women) presenting a weaker D reaction (< 3+ before the 
indirect antiglobulin test phase (IAT)) or a normal strength 
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of 4+ with anti-D and negative direct antiglobulin test 
(DAT) were referred to our immunohematology reference 
laboratory (IRL).
The D phenotype was determined by the classic tube 
technique using up to three sources of anti-D: Gamma 
(IgM GAMA401 + IgG F8D8, ImmucorGamma, Norcross, 
GA), Novaclone (DBL; IgM D175–2 + IgG D4151E4, 
ImmucorGamma), and BioClone (IgM MAD2 + IgG 
[polyclonal], Ortho-Clinical Diagnostics, Markham, Ontario, 
Canada). The D antibodies were identified using the IAT gel 
card technique (ID-Micro Typing System, Ortho-Clinical 
Diagnostics) with Héma-Québec’s red blood cell (RBC) 
panels. To distinguish autoantibodies from alloantibodies, 
autoadsorptions were performed if the patient had not 
been transfused in the last 3 months. An acid elution was 
performed following the manufacturer’s instructions (EluKit 
Plus, Immucor Gamma) for the samples with positive DAT. 
The eluate was tested with D+ and D– RBCs.
Molecular Biology
All samples were analyzed at the molecular level in our 
Research and Development Laboratory. Messenger RNA 
was studied in all cases. Genomic DNA was analyzed only 
for the weak D type 42.
RNA
The reticulocyte-enriched buffy coat from a 7-mL 
EDTA blood tube was transferred to a fresh 2-mL tube 
containing 1 mL of Trizol (Invitrogen, Burlington, Ontario, 
Canada) and mixed well, or 500 µL of whole blood was 
added to RNAlater (Applied Biosystems Inc. [ABI], 
Carlsbad, CA). The RNA isolation was performed following 
the manufacturers’ specifications. RNA was quantified, 
reverse transcribed, and amplified by using the One-Step 
RT-PCR (Qiagen, Mississauga, Ontario, Canada). Forward 
primer 397 located in RHD/RHCE 5′ end, 5′-cac-agg-atg-
agc-tct-aag-tac-3′, and reverse primer 625 located in RHD 
3′UTR, 5′-taa-atg-gtg-aga-ttc-tcc-tc-3′, were used.10,21 The 
full 1446-bp transcript was gel purified and sequenced (ABI 
3130xl Genetic Analyzer). The sequence was compared with 
Genbank X63097.
DNA
Two hundred microliters of EDTA-collected blood 
was kept at –80°C before DNA extraction using QIAamp 
mini blood kit (Qiagen) following manufacturer’s 
instructions. For weak D type 42 samples, RHD exon 9 was 
amplified from genomic DNA by classic touchdown PCR 
procedure. The PCR master mix contained 5% glycerol, 1× 
AmpliTaq Gold Buffer II, 2.5 mM MgCl2, 200 µM dNTPs, 
2.5 U AmpliTaq Gold, and 0.35 µM of forward primer 
560-RHD-i8-67F, 5′-tga-gat-act-gtc-gtt-ttg-aca-cac-aat-
act-tc-3′ located in RHD intron 8, and reverse primer 561- 
RGD-i9+62R, 5′-gtt-tta-ctc-ata-aac-agc-aag-tca-aca-tat-
atc-ct-3′, located in RHD intron 9.13 The hybrid Rhesus 
box was also examined following the process published by 
Wagner and colleagues.22
Weak D Type 42 PCR-SSP
A PCR–sequence-specific primer (SSP) assay was 
designed to facilitate the analysis of the weak D type 42. 
Genomic DNA was amplified with forward primer 560 
described previously and reverse primer 1034-wRHD-42-
as 5′-cta-tca-cgt-taa-tag-gtg-aac-aat-ctt-acC-A-3′ located 
part in RHD exon 9 and part in intron 9. The ‘c’ was 
mutated in the primer to avoid a long ‘a’ stretch. A 202-bp 




The samples described in the course of this study were 
referred to our IRL because of a weak D phenotype or 
the presence of anti-D in D+ patients with negative DAT. 
Most consisted of prenatal follow-up and surgery patients 
for whom an alloimmunization was possible through 
pregnancy or transfusion. Table 1 summarizes the serology 
and molecular biology results.
The reactivity with the anti-D reagents ranged from 
0 to 4+. Most weak D type 42 samples reacted 1+ to 2+ 
with Gamma-clone and Novaclone. The BioClone gave no 
reactions, except with patient 11 (3+). Surprisingly, patient 
13 showed no reactivity with the three anti-D sources 
assayed. No adsorption-elution was attempted to clarify 
between a DEL and a D– phenotype.
In the case of weak D type 1 and weak D type 2, the 
anti-D reactivity was on average 2+ with the three reagents, 
except for the sample from patient 18 (4+), which presented 
autoanti-D and autoanti-C. The situation was different for 
the weak D type 45 sample and for the two samples with the 
DNB phenotype: in all three the reactivity was 4+ and an 
alloanti-D was found.
Molecular Biology
The mRNA sequence analysis of all 26 samples showed 
a polymorphism that could explain the weak D phenotype 
or the presence of alloanti-D. Seventeen samples were 
found to be weak D type 42 (65.4%, 1 man and 16 women), 
five were weak D type 1 (19.2%, 2 men and 3 women), one 
sample was found to be weak D type 2 (3.8%, 1 woman), 
one was weak D type 45 (3.8%, 1 woman), and two were 
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DNBs (7.7%, 1 man and 1 woman). A hybrid Rhesus box was 
amplified in all cases, indicating a hemizygote RHD (Dd).
The cDNA profile of weak D type 42 on agarose gel is 
characterized by three distinct bands of lower molecular 
weight compared with normal cDNA (Fig. 1). To facilitate 
the analysis of the weak D type 42 variant, a PCR-SSP assay 
was designed. Figure 2 illustrates the clear results obtained 
for two normal control samples (lanes 3 and 4) and two 
weak D type 42 samples (lanes 5 and 6).
Discussion
Weak D phenotypes are thought to express quantitative 
D antigen variant. According to Wagner and Flegel,22 
Table 1. Serology and molecular biology results
Anti-D reaction*
Case Age/Sex Diagnosis Pregnancy Transfusion Gamma Novaclone BioClone RHD variant Antibodies
1 28/F Pregnancy Yes No 1+ 1+ NT Weak D type 42 No
2 62/F Renal failure Yes Yes 1+ 1.5+ NT Weak D type 42 No
3 74/F Surgery No Yes NT 2+ NT Weak D type 42 autoanti-D
alloanti-C
(no anti-G)
4 30/F Pregnancy Yes No 2+ 2+ NT Weak D type 42 No
5 75/F Anemia Yes Yes 2+ 2+ NT Weak D type 42 autoanti-D
alloanti-C
(anti-G unlikely)†
6 80/F Anemia Yes Yes NT 2+ NT Weak D type 42 No
7 80/M Angioplasty No No NT 2+ NT Weak D type 42 No
8 22/F Postpartum Yes No 2+ NT 0 Weak D type 42 No
9 46/F Surgery Yes Yes NT 2+ NT Weak D type 42 alloanti-D
alloanti-C
(anti-G?)
10 20/F Unknown Unknown Unknown 2+ NT 0 Weak D type 42 No
11 26/F Pregnancy Yes No 2+ NT 3+ Weak D type 42 No
12 24/F Pregnancy Yes No 1+ 2+ NT Weak D type 42 No
13 66/F Surgery No Yes 0 0 0 Weak D type 42 alloanti-D
alloanti-C
(anti-G?)
14 65/F Surgery Yes Yes 1+ 2+ NT Weak D type 42 No
15 80/F Cancer Unknown No NT 1+ NT Weak D type 42 autoanti-D
alloanti-C
(anti-G unlikely)
16 24/F Pregnancy Yes No 1+ 1.5+ NT Weak D type 42 No
17 36/F Pregnancy Yes No 2.5+ 2+ 0 Weak D type 42 anti-D?
alloanti-C
(anti-G?)
18 65/F Hysterectomy Yes Yes NT 4+ NT Weak D type 1 autoanti-D
autoanti-C
19 33/F Pregnancy Yes No 2+ 2+ NT Weak D type 1 No
20 65/M Unknown No Yes 2+ 2+ 2+ Weak D type 1 No
21 33/F Pregnancy Yes Unknown 2+ 2+ 2+ Weak D type 1 No
22 18/M Splenectomy No No NT 1+ NT Weak D type 1 No
23 32/F Pregnancy Unknown Yes NT 2+ NT Weak D type 2 No
24 81/F Cancer Unknown Yes NT 4+ NT Weak D type 45 alloanti-D
25 51/F Surgery Yes Yes NT 4+ NT DNB alloanti-D
alloanti-K
26 53/M Aortic rupture No Yes NT 4+ NT DNB alloanti-D
*Gamma (ImmucorGamma; IgM GAMA401+IgG F8D8); Novaclone (DBL; IgM D175-2+IgG D4151E4); BioClone (Ortho; IgM MAD2+IgG [polyclonal]).
†Recently transfused.
NT = not tested.
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position 1226, involved in the weak D type 42 variant 
(1226A>T, K409M), should be located inside the cell, which 
meets the weak D definition. In the original publication 
describing this D variant, no alloantibodies were reported.7 
In our study, anti-D as well as anti-C was present in the 
serum of six patients. Some were classified as alloanti-D or 
-C, whereas others were autoanti-D or -C. Anti-G was not 
ruled out in these cases because adsorption-elution is only 
performed on prenatal cases according to our procedures.
The weak D type 1 patients had no anti-D, except patient 
18, who had autoanti-D. The only patient with a weak D 
type 45 had alloanti-D as did the two patients with the 
DNB. Other D variants have been reported to be associated 
with alloimmunization.3,6,8,11,13,15–17
The variation in the D typing observed among weak 
D type 42 patients could be attributable to the D antigen 
density at the RBC surface. No flow cytometry analyses 
were performed to prove this hypothesis. In the case of 
patient 13, no reactions were seen with the three anti-D 
sources used. Because the DAT on the patient’s sample 
was positive, the analyses were not tested by the IAT. An 
adsorption-elution would have been useful to establish 
a clear D type for this patient (DEL or D), but additional 
sample was not available.
During the course of this study, we have been aware of 
only one case of HDFN involving a weak D type 42 mother 
(patient 17). This patient had a suspected anti-D and an 
alloanti-C. We could not determine whether the HDFN was 
caused by the suspected anti-D or the alloanti-C.
During the years, several studies have shown that weak 
D types 1, 2, and 3 are the most prevalent in Caucasians. 
In our multi-generation French Canadian population, we 
see a different result, in which weak D type 42 seems to 
be the most frequent. This could be caused by a founder 
effect directly linked to our history. Immigration to Quebec 
started in the early 17th century. Most immigrants came 
from France. By the end of the 18th century, land along 
the St. Lawrence River was occupied. To make room for 
the continued arrival of new immigrants, territories were 
opened for colonization and closed a few years later when 
enough families had settled. This geographic particularity 
1 2 3 4
Normal RHD cDNA
Fig. 1 RHD RT-PCR profile. After mRNA isolation, a reverse 
transcription followed by a PCR amplification was performed. The 
amplified products were visualized on an agarose gel. In a normal 
sample (lane 3), three major bands were observed. In a weak D type 
42 sample (lane 4), three major bands of lower molecular weight 
were consistently seen. (Lane 1, molecular weight marker; lane 2, 
no DNA control; lane 3, normal RHD sample; lane 4, weak D type 
42 sample [case 4 in Table 1].)
Fig. 2 PCR-SSP assay for weak D type 42. This multiplex PCR 
assay was done on genomic DNA. The amplified HGH internal 
control was present in all samples (432 bp). The band specific for 
the weak D type 42 allele at 202 bp was observed only when this 
variant allele was present. (Lane 1, molecular weight marker; lane 2, 
no DNA control; lanes 3 and 4, normal RHD samples; lanes 5 and 
6, weak D type 42 samples [cases 7 and 8 in Table 1].)
HGH
Weak D type 
42 allele 
specific band
1 2 3 4 5 6
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limited access to a diversified genetic background, causing 
a founder effect. It is particularly observed in genetic 
diseases.24
Our blood donor population consists of 99.6 percent 
multi-generation French Canadians (Yvan Charbonneau, 
Ing., VP Exploitation Héma-Québec, personal 
communication). It would be interesting to evaluate the 
prevalence of the weak D type 42 in the general population. 
A preliminary study found no weak D type 42 samples 
(data not shown) among 500 D+ blood donors originating 
from different regions of the province. This study should be 
pursued in the near future.
Additional note: Since this work was submitted, 
more samples were analyzed. The total number of weak 
D type 42 samples has now reached 50. Additional RHD 
variant samples were found: nineteen weak D type 1, four 
weak D type 2, and six other unique variants.
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